Raloxifene

Introduction Overview

Generic Name

raloxifene

Brand Name

Evista

Dosage Form

oral tablet (60 mg)

Drug Class

Hormones / antineoplastics, Selective estrogen receptor modulators

Pharmacokinetics

Absorption: Raloxifene is administered orally, with the 60 mg tablet being the standard dosage form. After oral administration, raloxifene is absorbed from the gastrointestinal tract; however, it undergoes extensive first-pass metabolism, which significantly reduces its systemic bioavailability to approximately 2%. Peak plasma concentrations are typically reached 1 to 2 hours post-dose. Food does not appear to significantly affect the absorption of raloxifene, allowing it to be taken with or without meals. Due to its extensive hepatic metabolism, variability in liver enzyme activity among individuals can influence plasma levels and therapeutic efficacy.

Distribution: Following absorption, raloxifene exhibits high plasma protein binding (>95%), primarily to albumin, which limits its free fraction in circulation. The drug distributes widely into body tissues, with a large volume of distribution estimated at 234 liters, reflecting distribution into non-plasma compartments including bone tissue, which is crucial for its therapeutic effects. Raloxifene crosses cellular membranes to bind estrogen receptors in target tissues, including bone and breast tissue, accounting for its selective activity as a selective estrogen receptor modulator (SERM).

Metabolism: Raloxifene undergoes extensive hepatic metabolism primarily through glucuronidation in the liver by UDP-glucuronosyltransferase enzymes (notably UGT1A1 and UGT1A8). The parent drug is rapidly metabolized to inactive raloxifene glucuronides, which circulate as major metabolites in plasma. Cytochrome P450 enzymes have a minimal role in its metabolism, reducing the likelihood of interactions via this pathway. The enterohepatic recycling of raloxifene glucuronides prolongs its half-life by reabsorption from the intestine, contributing to sustained plasma levels.

Elimination: The elimination half-life of raloxifene is approximately 27 to 32 hours, allowing once-daily dosing. The drug and its glucuronide metabolites are primarily excreted via the feces (approximately 60%), with the remainder excreted in urine. Renal excretion of unchanged raloxifene is minimal. Due to its hepatic metabolism and fecal excretion, patients with hepatic impairment may experience altered pharmacokinetics and require monitoring. The prolonged half-life supports steady plasma concentrations with regular dosing, optimizing its pharmacodynamic effects in osteoporosis and breast cancer risk reduction.

Dosage Forms

Available Dosage Forms: Raloxifene is available exclusively as oral tablets containing 60 mg of the active ingredient. The tablets are indicated specifically for postmenopausal women for treatment and prevention of osteoporosis and reduction of invasive breast cancer risk.

Dosages for Adults and Adolescents: The standard adult dosage for raloxifene to treat or prevent osteoporosis as well as to reduce the risk of invasive breast cancer in postmenopausal women is 60 mg taken orally once daily. There are no approved dosages for pediatric populations or men, as raloxifene is indicated solely for postmenopausal female patients.

Specific Patient Populations: No dosage adjustments are routinely recommended for patients with renal impairment since renal elimination is minimal; however, caution is advised in patients with hepatic impairment due to altered metabolism. Raloxifene is contraindicated in pregnant or breastfeeding women as it may cause fetal harm. Postmenopausal women with a history of venous thromboembolism should avoid raloxifene due to increased clot risk. The drug is not indicated or recommended in men or premenopausal women.

Mechanism Of Action

Raloxifene is a selective estrogen receptor modulator (SERM) that exerts tissue-selective estrogen agonist and antagonist effects by binding to estrogen receptors (ER) alpha and beta. Its molecular mechanism is based on modifying receptor conformation upon binding, which differentially regulates gene transcription in various tissues.

In bone tissue, raloxifene acts as an estrogen agonist, binding ERs in osteoblasts and osteoclasts to decrease bone resorption and turnover. This reduces the rate of bone loss associated with estrogen deficiency post-menopause and leads to increased bone mineral density and strength.

Conversely, raloxifene acts as an estrogen antagonist in breast and uterine tissues. It binds the estrogen receptor but recruits co-repressor proteins rather than co-activators, preventing estrogen-stimulated transcription of genes involved in cellular proliferation. This anti-estrogenic effect in breast tissue reduces the risk of developing estrogen receptor positive invasive breast cancer.

Raloxifene’s unique modulation of estrogen receptors provides therapeutic benefits by preserving bone mass while simultaneously inhibiting breast cancer cell growth pathways. Clinical trials have demonstrated raloxifene’s efficacy comparable to that of estrogen therapy for osteoporosis, but with a significantly reduced risk of stimulating breast or endometrial tissue. This differential receptor modulation distinguishes raloxifene from traditional hormone replacement therapies and accounts for its clinical utility and safety profile in postmenopausal women.

Pharmacological Actions

Selective estrogen receptor modulation with tissue-specific agonist/antagonist effects
Estrogen agonist activity on bone tissue to reduce bone resorption and increase bone mineral density
Estrogen antagonist activity in breast tissue to reduce risk of invasive estrogen receptor positive breast cancer
Reduction of vertebral fracture risk in postmenopausal osteoporosis
Anti-resorptive effects similar to estrogen without stimulating endometrial proliferation
Modulation of gene transcription through altered recruitment of co-regulatory proteins to ER
Improvement of lipid profiles by decreasing total cholesterol and low-density lipoprotein cholesterol
No significant stimulation of uterine tissue unlike estrogen therapy
Reduction of bone turnover markers indicating decreased bone loss
Potential cardioprotective effects related to lipid modulation
Minimal effects on coagulation factors but increased risk of venous thromboembolism
Oral selective estrogen receptor modulation with a prolonged half-life supporting once-daily dosing

Therapeutic Or Clinical Uses

Treatment of osteoporosis in postmenopausal women to increase bone mineral density and reduce fracture risk
Prevention of osteoporosis in postmenopausal women at risk of bone loss
Reduction in risk of invasive estrogen receptor positive breast cancer in postmenopausal women with osteoporosis
Reduction in risk of invasive breast cancer in postmenopausal women at high risk for the disease
Use as an alternative to hormone replacement therapy for bone protection in patients contraindicated for estrogen
Adjunctive therapy along with calcium and vitamin D supplementation for bone health maintenance
Use in women who are intolerant or contraindicated to bisphosphonates for osteoporosis
Part of comprehensive management for postmenopausal bone health including lifestyle modification and exercise
Therapeutic option for women seeking pharmacologic prevention of breast cancer alongside osteoporosis treatment
Off-label use considerations for prevention of breast cancer risk in selected patients based on clinical judgment

Side Or Adverse Effects

Hot flashes and vasomotor symptoms commonly reported during therapy
Leg cramps and muscle spasms as a frequent musculoskeletal adverse effect
Peripheral edema presenting as swelling in hands, feet, or ankles
Joint pain and stiffness (arthralgia) during treatment
Flu-like symptoms including malaise and fatigue
Increased sweating or hyperhidrosis
Risk of venous thromboembolism including deep vein thrombosis, pulmonary embolism, and retinal vein thrombosis
Rare reports of allergic reactions such as rash, urticaria, or angioedema
Potential for ischemic stroke, particularly in patients with additional risk factors
Gastrointestinal disturbances including nausea or abdominal pain
Possible effects on liver function tests in rare cases
Increased risk of leg swelling or localized pain suggesting thrombosis
Breast tenderness or changes in breast tissue warranting clinical evaluation
Headache and dizziness in some patients
Rare reports of vaginal bleeding or spotting

Precautions

Discontinue raloxifene at least 3 days prior to and during periods of prolonged immobilization or major surgery to reduce thromboembolism risk
Advise patients to report symptoms such as calf pain, swelling, chest pain, or sudden shortness of breath immediately
Assess patient history for prior venous thromboembolism before initiating therapy
Use cautiously in patients with moderate to severe hepatic impairment due to altered drug metabolism
Do not use in premenopausal women or men due to lack of established safety and efficacy
Monitor patients regularly for signs of stroke or thrombotic events during treatment
Encourage adequate intake of calcium and vitamin D concomitantly to maximize bone health benefits
Avoid concomitant use with other estrogen-containing products or hormone replacement therapy
Advise patients to avoid prolonged immobility or sitting during travel while on therapy
Pregnancy and breastfeeding are contraindications due to potential fetal harm
Regular breast self-exams and mammography are recommended to monitor breast health
Use caution in patients with a history of hypertriglyceridemia induced by estrogen therapy
Evaluate baseline and periodic liver function tests in patients with pre-existing liver disease
Inform patients about the potential for hot flashes as a side effect
Consider risk-benefit assessment in patients with cardiovascular risk factors

Warnings

Increased risk of venous thromboembolism including deep vein thrombosis and pulmonary embolism; contraindicated in patients with history of thromboembolic events
Potential increased risk of fatal stroke, especially in patients with cardiovascular risk factors such as smoking, hypertension, or prior stroke
Raloxifene use is contraindicated during pregnancy and breastfeeding due to risk of harm to the fetus and infant
Not indicated in men or premenopausal women; use outside approved populations is not recommended
Patients undergoing prolonged immobilization or major surgery should discontinue raloxifene temporarily to reduce thrombotic risk
May cause serious allergic reactions including angioedema or anaphylaxis in rare cases
Warnings regarding possible breast changes including lumps or tenderness warrant prompt medical evaluation
Risk of ocular vein thrombosis necessitates monitoring for symptoms such as visual changes
Close monitoring required in patients with cardiovascular disease, hypertension, or hyperlipidemia
Use with caution in patients with elevated triglycerides as raloxifene may exacerbate lipid abnormalities
Patients should be informed about signs and symptoms of thromboembolism and instructed to seek immediate medical help if they occur
Regular monitoring of bone density and mammography is advised to ensure therapeutic effectiveness and safety
Avoid concurrent use with other agents that increase thrombotic risk unless medically necessary
Discontinue therapy if any unexplained vaginal bleeding or breast changes are detected.

Contraindication

History of venous thromboembolism including deep vein thrombosis or pulmonary embolism
Known hypersensitivity to raloxifene or any component of the formulation
Pregnancy or women who may become pregnant due to potential fetal harm
Breastfeeding mothers due to risk of drug transfer via breast milk
Active or past history of thromboembolic events or retinal vein thrombosis
Pre-menopausal women and men as safety and efficacy have not been established
Patients with unexplained uterine bleeding until cause is determined
Concurrent use of estrogen-containing medications or hormone replacement therapy
Severe hepatic impairment where metabolism of raloxifene may be significantly affected
Known hypersensitivity to other selective estrogen receptor modulators may warrant caution
Patients with a prior history of stroke or transient ischemic attack may require risk assessment before use
Patients with hypertriglyceridemia caused by estrogens due to potential worsening
Malignant or pre-malignant uterine conditions without proper clinical evaluation

Drug Interactions

Cholestyramine can significantly reduce raloxifene absorption and plasma levels when coadministered; avoid concomitant use or separate administration by several hours
Warfarin and other anticoagulants may have altered effect when given with raloxifene; monitor coagulation parameters closely
Concurrent use with estrogen-containing contraceptives or hormone replacement therapy may reduce raloxifene efficacy and increase risk of adverse effects
Drugs inducing UDP-glucuronosyltransferase enzymes could theoretically increase raloxifene metabolism and reduce effectiveness
Medications that increase risk of thromboembolism when combined with raloxifene may potentiate clotting risk
Concomitant use with other agents affecting bone metabolism (e.g., bisphosphonates) requires monitoring for additive effects
Rifampin or other hepatic enzyme inducers may alter raloxifene plasma levels by inducing glucuronidation pathways
Cytochrome P450 inhibitors or inducers have minimal interaction risk due to limited CYP metabolism of raloxifene
Concurrent use of drugs with narrow therapeutic indices metabolized via glucuronidation might require caution
Calcium and vitamin D supplements do not interact adversely but should be taken as recommended to optimize bone health
Herbal supplements with estrogenic activity (e.g., black cohosh) may interfere with raloxifene effects
Alcohol consumption has not shown significant interaction, but patients should use moderation
Drugs causing edema or increasing leg swelling could exacerbate peripheral edema seen with raloxifene
Concurrent use of erythromycin or ketoconazole has not shown clinically significant interactions
Drug interactions that alter plasma protein binding are unlikely to influence raloxifene significantly due to high binding affinity

Preparations Of The Drug

Raloxifene Hydrochloride Tablets 60 mg for oral administration
Commercially available under the brand name Evista
Supplied as film-coated tablets to facilitate swallowing and improve stability
Packaged in blister packs or bottles depending on manufacturer and country
Tablets are intended for once daily oral dosing
Storage recommended at room temperature, protected from moisture and heat
No injectable or alternate formulations currently marketed
Formulations are designed for postmenopausal women with standardized dosage of 60 mg
Manufactured to comply with USP standards for potency and purity
May be available in generic forms depending on country regulations
Package inserts include detailed information on dosing, contraindications, and side effects
Pharmaceutical formulations do not contain estrogen but act as estrogen receptor modulators
Available through prescription only due to potential for serious adverse effects
Regular quality control testing ensures stability and bioavailability of tablets
Patient information leaflets accompany packaging to guide proper administration and precautions